- Conditions
- Central Nervous System Tumors, Brain Tumor
- Interventions
- temozolomide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 21,412
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
- Interventions
- temsirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Duarte, California • Los Angeles, California + 11 more
- Conditions
- Breast Cancer
- Interventions
- YM155, Docetaxel
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
- Conditions
- Esophageal Cancer
- Interventions
- capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy
- Drug · Genetic · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cisplatin, Docetaxel, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Azacytidine, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage II Colon Cancer, Stage III Colon Cancer
- Interventions
- Exercise
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC)
- Interventions
- NMS-01940153E
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Orange, California • St Louis, Missouri
- Conditions
- Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
- Interventions
- ALN-HSD, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 61
- States / cities
- Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more
- Conditions
- Verruca Vulgaris, Warts, Common Wart
- Interventions
- VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
- Drug
- Lead sponsor
- Veradermics, Inc.
- Industry
- Eligibility
- 9 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
- Conditions
- Lice Infestations
- Interventions
- MALG
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Orange, California • Sacramento, California • Aurora, Colorado + 22 more
- Conditions
- Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
- Interventions
- Gemcitabine, 9-ING-41, Docetaxel
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 10 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
- Interventions
- Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide
- Drug
- Lead sponsor
- Khalil Choucair
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more
- Conditions
- Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
- Interventions
- Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Letrozole
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
- Conditions
- Anorexia, Cachexia, Head and Neck Cancer, Quality of Life
- Interventions
- megestrol acetate, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Interventions
- BNT111, Cemiplimab
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more
- Conditions
- Acne Vulgaris
- Interventions
- ASC-J9 cream, placebo
- Drug
- Lead sponsor
- AndroScience Corp
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Fremont, California • San Diego, California • Boise, Idaho + 7 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 4 more
- Conditions
- Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
- Interventions
- ribociclib, Trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Fayetteville, Arkansas • Duarte, California • New Haven, Connecticut + 3 more